RGS20

Across TCGA pan-cancer cohorts, RGS20 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RGS20 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RGS20 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RGS20 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, LUAD, and LSCC are the cancer types where RGS20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.490	0.247	.012	6	view →
LUAD	OS	Quartile	All	0.459	0.839	.044	2	view →
LSCC	DFS	Median	All	0.239	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RGS20–GBM (DFS)

Open the GBM breakdown →